Odyssey Therapeutics priced and launched its initial public offering, raising $279 million at $18 per share, plus an additional $25 million from a concurrent private stock sale at the same price. The company’s IPO follows a prior delay more than a year earlier and positions Odyssey to begin Nasdaq trading under the ticker ODTX. Odyssey’s proceeds come amid investor demand for larger biotech offerings, with the company highlighting a venture-backed funding base that totals $727 million. The IPO marks another addition to the year’s slate of drug company debuts after an extended period in which biotech listings slowed relative to prior years. The move is significant for the autoimmune pipeline segment, where Odyssey is aiming to translate clinical progress into public-market scale with access to additional capital for development.